Navigation Links
Chi-Med Announces Positive Phase II Proof-of-Concept Data for,HMPL-004 in Ulcerative Colitis

n increase from around 300,000 patients in 2001. Potentially a further two to three times as many individuals may suffer from Ulcerative Colitis but are currently undiagnosed. Crohn’s Disease is more prevalent with an estimated 558,000 cases in the US in 2005. The US market for Ulcerative Colitis drugs was estimated to be US$420 million in 2002 and is expected to reach US$500 million by 2012, a CAGR of four percent. The US market for Crohn’s Disease drugs was estimated to be US$590 million, growing to around US$980 million by 2012. In both cases, the global market is estimated to be twice the size of the US. Global sales of Ulcerative Colitis drugs are estimated to reach US$1 billion by 2012 and, for Crohn’s Disease, the estimate is around US$2 billion. Current treatments include Aminosalicylates (5-ASAs) to reduce and control inflammation. In addition, Corticosteroids and Immunomodulators are prescribed for patients who do not respond to first line treatments.


About HMPL-004

HMPL-004 acts on multiple cellular targets in the inflammatory signal transduction pathways resulting in suppressed inflammation cytokine expression including TNF-?, IL-1? and IL-6. HMPL-004 was demonstrated to inhibit TNF-? and IL-1? production in cell-based assays. HMPL-004 is also able to inhibit NF-kB activation. NF-kB is a family of transcriptional factors that regulate a wide spectrum of genes critically involved in host defence and inflammation. The mechanism of action of HMPL-004 was further supported in inflammatory bowel disease pre-clinical models. Treatm
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:12/24/2014)... 23, 2014  Advanced Medical Isotope Corporation ("AMIC") ... in the development of brachytherapy devices and medical ... that it has filed a de novo ... ("FDA") for marketing clearance for its patented Y-90 ... U.S. Food, Drug and Cosmetic Act (the "Act").  ...
(Date:12/24/2014)... , Dec. 23, 2014   Assurex Health, ... decision support to healthcare providers for behavioral health ... has secured $30 million in equity financing from ... C. Drosos , President and Chief Executive Officer. ... adoption and development of Assurex Health,s GeneSight ...
(Date:12/24/2014)... SANTA BARBARA, Calif. , Dec. 23, 2014 ... the Junior Doctors, Association of Sierra Leone ... Sierra Leone for the treatment of local ... While a new dedicated Ebola care center was ... Ebola virus, the facility is not available for local Sierra ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2
(Date:12/25/2014)... When head lice hits a home or ... to get rid of it while keeping it from taking ... now have the solution right in their neighborhood: Lice ... Troopers provides full spectrum head lice screening and treatment services ... Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest and South ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. ... chronic illnesses can receive effective, less expensive care from a ... to a team of dedicated health care professionals, a new ... ill and need either hospitalization or a trip to the ... home clinic at the University of Texas in Houston versus ...
(Date:12/25/2014)... -- Overeating is common during the holidays, but there are ... says. "Don,t arrive at a party hungry. It may ... be attending a party, but deprivation leads to hunger, and ... Westchester Hospital in Mount Kisco, N.Y., said in a hospital ... day and even to have a snack before attending a ...
(Date:12/25/2014)... Thompson HealthDay Reporter WEDNESDAY, ... in on a "fountain of youth" drug that can delay ... adults, a new study suggests. Seniors received a significant ... targets a genetic signaling pathway linked to aging and immune ... The experimental medication, a version of the drug rapamycin, ...
(Date:12/25/2014)... December 25, 2014 Thousands of transvaginal ... forward in a number of multidistrict litigations currently underway ... Bernstein Liebhard LLP reports. According to an Order issued ... convene a Joint Status Conference in all of the ... have been directed to submit a proposed agenda to ...
Breaking Medicine News(10 mins):Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4
... proportion of patients with advanced cancer and a life ... common cancer screening tests that are unlikely to provide ... 13 issue of JAMA . Cancer ... (PSA) and colonoscopy, evaluate asymptomatic patients for the detection ...
... Goodwin HealthDay Reporter , TUESDAY, Oct. 12 (HealthDay ... transfusions do just as well as those who receive more, ... varies widely among U.S. hospitals. The studies are published ... the American Medical Association . In the first study, ...
... GABLES, FL (October 12, 2010)--Still hampered by workforce shortages ... care to the full extent of their education and ... the arm they need to transform their profession with ... recommending sweeping changes for improving their profession. The report, ...
... By Kathleen Doheny HealthDay Reporter , TUESDAY, Oct. ... cancer care has long been known by researchers, with ... cancer treatments than white patients. "Less well known is ... something else contributing?" said Dr. Rachel Freedman, a medical ...
... of a large Phase-III clinical trial have shown that ... a hard-to-treat group of rare cancers that affect particular ... European Society for Medical Oncology (ESMO), Dr Marianne Pavel ... improved progression-free survival by 5.1 months in patients with ...
... population ages, health care epidemiologist Padma Kaul and cardiologist Paul ... the University of Alberta, want health-care professionals to talk to ... it be at home, in hospital or a palliative care ... recent study, that the majority of heart failure patients pass ...
Cached Medicine News:Health News:Considerable proportion of patients with advanced cancer continue to undergo common cancer screening 2Health News:Considerable proportion of patients with advanced cancer continue to undergo common cancer screening 3Health News:Heart Surgery Patients Do Fine With Fewer Blood Transfusions: Study 2Health News:Heart Surgery Patients Do Fine With Fewer Blood Transfusions: Study 3Health News:National committee releases findings on transforming and improving the nursing profession 2Health News:Insurance, Income Don't Explain 'Race Gap' in Breast Cancer Care 2Health News:Insurance, Income Don't Explain 'Race Gap' in Breast Cancer Care 3Health News:Phase III study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors 2Health News:Medical researchers break down costs to care for heart failure patients at the end of life 2
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
The CE marked HF coagulator which meets the highest ISO safety features....
Finesse electrosurgical generator (100-120 VAC) utilizes a patented design that integrates the electrosurgical generator and smoke evacuation system into a single compact unit....
Medicine Products: